Suppr超能文献

预测乳腺浸润性导管癌肿瘤复发的新标准。

New criteria to predict tumor recurrence in invasive ductal carcinoma of the breast.

作者信息

Nozoe Tadahiro, Mori Emiko, Iguchi Tomohiro, Ezaki Takahiro

机构信息

Department of Surgery, Fukuoka Higashi Medical Center, Koga, Japan.

出版信息

Int Surg. 2013 Oct-Dec;98(4):283-8. doi: 10.9738/INTSURG-D-12-00029.1.

Abstract

Incidence of triple-negative breast cancer (TNBC), which is cancer without expression of ER, PgR, and HER2, and nuclear grade (NG) are closely correlated with malignant potential of breast cancer. However, criteria to determine aggressiveness of breast cancer based on these factors have not been elucidated. The aim of this study was to create criteria using these factors to predict tumor recurrence in invasive ductal carcinoma (IDC) of the breast. One hundred and seventy-nine patients with IDC of the breast, which had been treated by surgical resection, were included. One point was added for each factor of the two categories of TNBC and NG 3. The sum of the scores (TGS 0, 1, or 2) was calculated. Significant difference was observed between TGS and the incidence of tumor recurrence (P < 0.0001). Moreover, significant differences were observed regarding relapse-free survival (RFS) between patients with TGS 0 and TGS 1 (P < 0.0001) and patients with TGS 1 and TGS 2 (P = 0.024). TGS might contain a clinical advantage as a useful predictor for tumor recurrence of IDC of the breast and could classify prognosis of the patients with a preferable stratification.

摘要

三阴性乳腺癌(TNBC)是一种不表达雌激素受体(ER)、孕激素受体(PgR)和人表皮生长因子受体2(HER2)的癌症,其发病率与核分级(NG)与乳腺癌的恶性潜能密切相关。然而,基于这些因素来确定乳腺癌侵袭性的标准尚未阐明。本研究的目的是利用这些因素制定标准,以预测乳腺浸润性导管癌(IDC)的肿瘤复发情况。本研究纳入了179例接受手术切除治疗的乳腺IDC患者。TNBC和NG 3这两类因素,每一类中的每个因素计1分。计算得分总和(TGS为0、1或2)。观察到TGS与肿瘤复发率之间存在显著差异(P < 0.0001)。此外,TGS为0的患者与TGS为1的患者之间以及TGS为1的患者与TGS为2的患者之间,在无复发生存期(RFS)方面也观察到显著差异(P < 0.0001和P = 0.024)。TGS作为乳腺IDC肿瘤复发的有用预测指标可能具有临床优势,并且可以对患者的预后进行较好分层的分类。

相似文献

1
New criteria to predict tumor recurrence in invasive ductal carcinoma of the breast.
Int Surg. 2013 Oct-Dec;98(4):283-8. doi: 10.9738/INTSURG-D-12-00029.1.
5
Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
Breast Cancer. 2017 Sep;24(5):667-672. doi: 10.1007/s12282-017-0753-4. Epub 2017 Jan 20.
10
14-3-3ζ promoted invasion and lymph node metastasis of breast invasive ductal carcinoma with HER2 overexpression.
Pathol Res Pract. 2021 Nov;227:153619. doi: 10.1016/j.prp.2021.153619. Epub 2021 Sep 22.

本文引用的文献

1
Cancer survivors in the United States: a review of the literature and a call to action.
Int J Med Sci. 2012;9(2):163-73. doi: 10.7150/ijms.3827. Epub 2012 Jan 17.
2
How do I treat "triple-negative" disease.
Curr Treat Options Oncol. 2011 Dec;12(4):369-88. doi: 10.1007/s11864-011-0168-y.
3
Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Breast Cancer. 2011 Jul;18(3):165-73. doi: 10.1007/s12282-011-0254-9. Epub 2011 Feb 3.
4
Characteristics of triple-negative breast cancer.
J Cancer Res Clin Oncol. 2011 Feb;137(2):183-92. doi: 10.1007/s00432-010-0957-x. Epub 2010 Nov 11.
5
Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer.
Med Oncol. 2011 Dec;28 Suppl 1:S75-9. doi: 10.1007/s12032-010-9715-9. Epub 2010 Oct 21.
6
Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
Surgery. 2010 Aug;148(2):386-91. doi: 10.1016/j.surg.2010.05.018. Epub 2010 Jul 1.
7
Triple-negative breast cancer: a short review.
Am J Clin Oncol. 2010 Dec;33(6):637-45. doi: 10.1097/COC.0b013e3181b8afcf.
10
Triple-negative breast cancer: clinical features and patterns of recurrence.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34. doi: 10.1158/1078-0432.CCR-06-3045.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验